Director of TScan Therapeutics Barbara Klencke Buys 18% More Shares
Director of TScan Therapeutics Barbara Klencke Buys 18% More Shares
Whilst it may not be a huge deal, we thought it was good to see that the TScan Therapeutics, Inc. (NASDAQ:TCRX) Director, Barbara Klencke, recently bought US$56k worth of stock, for US$5.61 per share. While we're hesitant to get too excited about a purchase of that size, we do note it increased their holding by a solid 18%.
儘管這可能不是什麼大問題,但我們認爲很高興看到TScan Therapeutics, Inc.(納斯達克股票代碼:TCRX)董事芭芭拉·克倫克最近以每股5.61美元的價格購買了價值5.6萬美元的股票。儘管我們不願對如此規模的收購感到過於興奮,但我們確實注意到這使他們的持股量穩步增加了18%。
TScan Therapeutics Insider Transactions Over The Last Year
去年 tScan Therapeutics 的內幕交易
In the last twelve months, the biggest single purchase by an insider was when insider Timothy Barberich bought US$142k worth of shares at a price of US$4.97 per share. Even though the purchase was made at a significantly lower price than the recent price (US$5.69), we still think insider buying is a positive. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.
在過去的十二個月中,內部人士最大的一次收購是內部人士蒂莫西·巴貝里奇以每股4.97美元的價格購買了價值14.2萬美元的股票。儘管此次收購的價格明顯低於近期價格(5.69美元),但我們仍然認爲內幕買入是積極的。儘管這確實表明內部人士認爲該股在較低的價格下被低估,但這筆交易並沒有告訴我們他們對當前價格的看法。
In the last twelve months insiders purchased 44.15k shares for US$224k. But insiders sold 7.50k shares worth US$43k. Overall, TScan Therapeutics insiders were net buyers during the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
在過去的十二個月中,內部人士以22.4萬美元的價格購買了4.15萬股股票。但內部人士出售了價值4.3萬美元的0.75萬股股票。總體而言,去年,TScan Therapeutics的內部人士是淨買家。下圖顯示了去年的內幕交易(公司和個人)。如果你想確切地知道誰賣了、賣了多少以及何時出售,只需點擊下圖!
![1724925617099](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240829/43057831-0-eb9ac52a28d91f5146039d6d610c745d.webp/bigjpg)
TScan Therapeutics is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.
TScan Therapeutics並不是內部人士唯一買入的股票。因此,來看看這份不爲人知的內幕收購公司的免費清單。
Insider Ownership
內部所有權
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. Our data suggests TScan Therapeutics insiders own 0.8% of the company, worth about US$2.3m. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. We prefer to see high levels of insider ownership.
測試公司領導者與其他股東之間一致性的另一種方法是查看他們擁有多少股份。我認爲,如果內部人士擁有該公司的大量股份,這是一個好兆頭。我們的數據顯示,TScan Therapeutics內部人士擁有該公司0.8%的股份,價值約230萬美元。但是,我們確實注意到,內部人士有可能通過私營公司或其他公司結構獲得間接利益。我們更願意看到高水平的內部所有權。
So What Do The TScan Therapeutics Insider Transactions Indicate?
那麼,TScan Therapeutics的內幕交易表明了什麼呢?
Our data shows a little insider buying, but no selling, in the last three months. That said, the purchases were not large. However, our analysis of transactions over the last year is heartening. While we have no worries about the insider transactions, we'd be more comfortable if they owned more TScan Therapeutics stock. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. While conducting our analysis, we found that TScan Therapeutics has 2 warning signs and it would be unwise to ignore these.
我們的數據顯示,在過去的三個月中,有少量內幕買入,但沒有賣出。也就是說,購買量並不大。但是,我們對去年交易的分析令人鼓舞。雖然我們不擔心內幕交易,但如果他們擁有更多的TScan Therapeutics股票,我們會更放心。雖然了解內部人士的所有權和交易情況是件好事,但在做出任何投資決策之前,我們一定要考慮股票面臨的風險。在進行分析時,我們發現TScan Therapeutics有兩個警告信號,忽視這些信號是不明智的。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
當然,通過尋找其他地方,你可能會找到一筆不錯的投資。因此,來看看這份有趣的公司的免費清單吧。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。